Disproportional response: a small company's current business is visibly outgrowing its own size
The model's full reasoning — Q4 2017 call → NOWe need to determine if management conveys that the business is currently outgrowing the company's size, with disproportionate scale relative to smallness. Look for statements about current activity, demand, commitments arriving at scale large relative to company size. In the transcript, management discusses partnerships, J&J collaboration, CMS reimbursement, Phase 4 studies, etc. They mention growth rates, but do they explicitly say the company is small and what's happening is disproportionately large? They talk about J&J investing resources, PEAK programs, etc. But they also give guidance for 2018 sales of $300-310M, which is modest growth. They mention "we are well-positioned" but not necessarily that current business is outgrowing the company. They talk about opportunities but not in a way that conveys disproportion. They mention "we have not done a good job over the last couple of years of making sure that we've met the guidance" and they are being conservative. They talk about CMS as a major opportunity but it's pending. They talk about partnerships but not that they are overwhelmed. The question asks if management conveys that the business is currently outgrowing the company's size. I don't see explicit statements like "our current demand is far exceeding our capacity" or "we are a small company and this single contract is huge relative to us." They mention J&J's investment but that's a partnership, not necessarily a disproportion. They also mention "we are thrilled with the resources J&J is investing" but that's not about the company being small. They talk about growth rates of 6-10% which is not outsized. So likely NO. Check if any statement implies disproportion. For example, "The only single administration long acting local analgesic... uniquely positioned" but that's market position. They talk about "we have a number of clinician today using EXPAREL in very low doses" but that's off-label. They talk about "we are working with CMS" but that's prospective. They talk about "we have a list of hospitals where the only person that has the relationships... have been non-EXPAREL employee" but that's about J&J. They don't say "our company is small and this is huge." They do mention "we have plenty of capacity" and "we will give Swindon as much material as they can make" but that's about manufacturing.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| KOPN | Kopin Corporation | Q4 2023 | 2024-03-14 | C+ |
| TMCI | Treace Medical Concepts, Inc. | Q2 2022 | 2022-08-13 | B+ |
| VNRX | VolitionRx Limited | Q1 2022 | 2022-05-12 | F |
| FLUX | Flux Power Holdings, Inc. | Q2 2022 | 2022-02-10 | D |
VNRX · Q1 2022 → YESThe question is: Does management convey that the business the company is doing RIGHT NOW is visibly outgrowing the company's own current size and setup? That current activity, demand, or commitments a...YES The transcript shows management explicitly describing the Heska deal (already signed and with $10M upfront received) as a long-term, multi-year commitment that will generate ongoing kit/component revenue "significantly greater" than the $28M milestones, with "millions of tests" expected each year — all while repeatedly noting the company is "not a big company" and that this is "the beginning of our commercial journey" after 12 years of R&D. They contrast this with their tiny current revenue ($114k) and cash position, framing the new activity as disproportionately large relative to their size.
TMCI · Q2 2022 → YESThe question is: Does management convey that the business the company is doing RIGHT NOW is visibly outgrowing the company's own current size and setup? That current activity, demand, or commitments a...YES Management explicitly describes the business as outgrowing its current setup in present-tense terms: they are “once again in the process of relocating to a larger headquarters facility” to meet “increased requirements” for training, R&D, warehousing, and infrastructure; the direct sales force has grown 52% to 123 quota-carrying reps and is already trending above the year-end 70% direct mix goal; surgeon penetration has reached 20% of the estimated 10,000 U.S. foot-and-ankle surgeons while procedure penetration is 4.6% of the 450,000 annual U.S.
KOPN · Q4 2023 → YESThe question is: Does management convey that the business the company is doing RIGHT NOW is visibly outgrowing the company's own current size and setup? That current activity, demand, or commitments a...YES The transcript shows management describing current activity (a $55 million backlog, a $20.5 million new order, follow-on orders, and tripled weapon-site volume expected in 2024) as large relative to the company’s still-small size and setup. They explicitly note the backlog is a “record level 10 years,” that they had to extend the holiday shutdown and retool the plant for a “significant increase in production,” and that they are “buying to that level of volume today” while remaining conservative on guidance.